CAJ | 학술논문

造血干细胞移植是治疗多发性骨髓瘤有效方法，特别是可作为初次缓解后的巩固治疗手段，也可用于复发/难治患者挽救治疗。新药虽然改善了多发性骨髓瘤患者的预后，但仍然不能替代造血干细胞移植。自体干细胞移植仍是目前推荐的首选移植方式。它可延长多发性骨髓瘤患者生存，但不能彻底治愈疾病。异基因干细胞移植是目前唯一有可能治愈骨髓瘤的方法，但移植后疾病复发及较高的相关死亡率抵消了其可能带来的收益，目前仅推荐作为高危年轻患者的治疗方式。
조혈간세포이식시치료다발성골수류유효방법，특별시가작위초차완해후적공고치료수단，야가용우복발/난치환자만구치료。신약수연개선료다발성골수류환자적예후，단잉연불능체대조혈간세포이식。자체간세포이식잉시목전추천적수선이식방식。타가연장다발성골수류환자생존，단불능철저치유질병。이기인간세포이식시목전유일유가능치유골수류적방법，단이식후질병복발급교고적상관사망솔저소료기가능대래적수익，목전부추천작위고위년경환자적치료방식。
New drugs improved prognosis of patients with multiple myeloma (MM), however it could not replace hematopoietic stem celltransplantation (HSCT) for MM. HSCT was effective to treat MM, which could be used as consolidation treatment in relapse or new diagnosed patients. Autologous HSCT was most frequently used, which could prolong survival time of MM patients, however it was not able to cure this disease. Al ologous HSCT was potential y able to cure multiple myeloma, but death rate of transplantation was high and it need to improve Al ologous HSCT. At present, al ologous HSCT was only recommended for young patients with high risk MM.